The Largest Online Global Physicians Community



Connect Globally Expand your medical network and Connect with physicians worldwide. Consult & Share with colleagues at your specialty. Choose the specialty channels of your interest.
Discuss Discuss & Collaborate with colleagues at your specialty and other specialties. Share your insights, experience and opinions. Comment to posts and publications of peers. Post text, pictures, videos and files using your real name or stay anonymous.
Stay Updated Case Studies, Medical Publications updates by specialty, E- Learning courses and second opinionfrom colleagues. Library by Specialty: Share & download files, presentation and images by specialty and topics. PubMed publications alerts
Groups Join and Create physician group & experts panels. Common interest, idea, activity or event. Online "Round Table" of specialist. Medical topic groups, Researches groups, Department groups, Management groups, Event groups, Ad hoc groups.
Research Manage & Communicate with all research sites through one international secure network. Promote your research & request for patient recruitment.
Honoraria Earn Honoraria for your knowledge and expertise. Participate in Surveys, Focus groups and Experts Panels, 2nd opinion consultations, Job offers.
Featured Posts

Hemiplegic migraine post Pfizer vaccination?

I have a young woman who 5years ago got weakness face arm leg with road it and. A challenge on a number of occasions produced the same result. About 12 hrs after Pfizer vaccine she developed facial droop and weakness arm and leg. MRI showed high t intensities compatible with a number of things like vasoconstriction, migraine. A previous scan a few years ago after head injury was normal. started candesartan and clopidogrel. Cleared over 5 days. Covered second vax with above RX, day two facial droop but no arm or leg symptoms. Anyone seen this? Any thoughts? 

Nationwide Study Shows BNT162b2 mRNA Vaccine Is Effective

WEDNESDAY, Feb. 24, 2021 (HealthDay News) -- The BNT162b2 mRNA vaccine is effective for COVID-19-related outcomes, including hospitalization, severe illness, and death, in a nationwide, mass vaccination setting, according to a study published online Feb. 24 in the New England Journal of Medicine.

Noa Dagan, M.D., from Clalit Health Services in Tel Aviv, Israel, and colleagues examined the effectiveness of the BNT162b2 mRNA vaccine using data from Israel's largest health care organization. All 596,618 persons who were newly vaccinated during Dec. 20, 2020, to Feb. 1, 2021, were matched to 596,618 unvaccinated controls. Study outcomes included documented infection with severe acute respiratory syndrome coronavirus 2, symptomatic COVID-19, COVID-19-related hospitalization, severe illness, and death.

The researchers found that at 14 through 20 days after the first dose and at seven or more days after the second dose, the estimated vaccine effectiveness was 46 and 92 percent, respectively, for documented infection; 57 and 94 percent for symptomatic COVID-19; 74 and 87 percent for hospitalization; and 62 and 92 percent for severe disease. For preventing death from COVID-19, the estimated effectiveness was 72 percent for days 14 through 20 after the first dose. Across age groups, the estimated effectiveness was consistent for documented infection and symptomatic COVID-19 in specific subpopulations, with potentially slightly lower effectiveness in those with multiple coexisting conditions.

"This study estimates a high effectiveness of the BNT162b2 vaccine for preventing symptomatic COVID-19 in a noncontrolled setting," the authors write. "These results strengthen the expectation that newly approved vaccines can help to mitigate the profound global effects of the COVID-19 pandemic."

Abstract/Full Text (subscription or payment may be required)

Copyright © 2020 HealthDay. All rights reserved. 

New Coronavirus Variant Surging in California

WEDNESDAY, Feb. 24, 2021 (HealthDay News) -- A coronavirus variant first identified in California is more contagious than previous forms of the virus and is spreading across the state, two new studies show.

One study revealed that compared with other variants, this variant produces twice as many viral particles inside the body and may be better at evading the immune system and vaccines, The New York Times reported.

The study also confirmed that the variant -- called B.1.427/B.1.429 and first detected in December -- has surged across California. The second study showed that the variant has spread rapidly in San Francisco's Mission District in the past few months. The studies have not yet been published in a scientific journal or subjected to peer review.

"I wish I had better news to give you -- that this variant is not significant at all," said Charles Chiu, M.D., a virologist at the University of California, San Francisco, and an author of the first study, The Times reported. "But unfortunately, we just follow the science."

The B.1.427/B.1.429 variant has been detected in 45 U.S. states to date and in several other countries, including Australia, Denmark, Mexico, and Taiwan. But so far, it has become widespread only in California. By late January, it had become the predominant variant in California, and cases caused by the variant are now doubling every 18 days, according to Chiu and colleagues.

The New York Times Article

Copyright © 2020 HealthDay. All rights reserved.

Vocês tem artigos científicos sobre Hipertensão Pulmonar pós covid19? Alguém está tratando ? Com qual droga? Tem ideia por que evoluem com Hipertensão Pulmonar?

Patiente de 60 ans avec Lymphome T.


J'ai une patiente de 60 ans qui suit une chimiothérapie pour un lymphome T, est-ce que elle doit se faire vaccinée ? 


Vaccination-side effects

What do you know about side effects 2 weeks after the vaccine Pfeizer-second dose.

Here are some of your thoughts on Vaccination

Should patients under immunosuppressive treatment be vaccinated against Covid-19? How about those who have recovered from Covid, when should they get vaccinated?

Over the past months, the G-Med community has been discussing vaccination decisions, its effects and advisability to patients suffering from different pre conditions. Immunodepression, diabetes, rheumatological issues, among several others, were some of the conditions debated in the G-Med community in light of the decision to vaccinate against Covid-19. Our physician-only community continues to debate this crucial topic, and to share their insights with their colleagues. 

Thank you for your thoughtful contribution. Here are some of the issues discussed:

G-Med at a glance: The community you created

Thank to your participation, 25,400 posts were published on G-med. In a single discussion, physicians from 48 countries shared their insights. Cases were posted and solved as fast as 14 hours.
Thank you for being part and helping our growing community flourish.

Here are some of your thoughts on Post-Covid

How are physicians from the G-Med community preparing themselves for the Post-Covid Era? What are Covid’s real impacts on the health of patients after recovering from the initial illness?

Over the past months, the G-Med community has been discussing one of tomorrow’s most challenging medical issues: Post-Covid conditions. From endocrinological conditions, neurological concerns, rheumatological impacts, among others, physicians from over 128 countries are sharing cases and receiving great insights from the community. 

Thank you for your thoughtful insights. Here are some of the issues discussed: